Overview
Status
Active
Registry date
2018-03-23
Share capital
5 000,00 PLN
Registered address
ul. Szańcowa 44/1, 01-458 Warszawa, Poland
Email
Electronic delivery address
AE:PL-44351-80751-VUAGE-22
Financials
Revenue history (in k)
Filing timeliness
3 of 6 financial statements were filed late (the longest delay 370 days for 2021).
- 202516/07/2026
- 202412/06/2025
- 202327/06/2024
- 202220/07/2023
- 202120/07/2023
- 202004/08/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 874.98kMedianUSD 1.06mAverageUSD 22.41m
Net profit
This companyUSD -28.88kMedianUSD 37.20kAverageUSD 879.46k
Operating costs
This companyUSD 899.54kMedianUSD 921.66kAverageUSD 21.08m
Assets
This companyUSD 496.78kMedianUSD 609.79kAverageUSD 11.85m
Industry
Authorized Representatives
Andrii Andreichenko – President of the Management Board
Valentyna Kirku – Management Board Member
Manner of representation
Each member of the management board is authorized to make declarations on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Andrii Andreichenkoage 34 | 50 | $675.31 | 50% |
Valentyna Kirkuage 46 | 50 | $675.31 | 50% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2018-04-11.
16 1020 3352 0000 1402 0339 5183
76 1020 3352 0000 1002 0339 7403
78 1020 3352 0000 1902 0339 7411
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Atradis Polskasp. z o.o. | $1,284,064.17 | atradis.pl | ||
| Eickemeyer - Veterinary Technology for Lifesp. z o.o. | $1,238,702.38 | eickemeyer.pl | ||
| Kleemed Pharmaceuticals Polandsp. z o.o. | $847,166.12 | kleemed.com.pl | ||
| Novisc Pharmasp. z o.o. | $806,018.56 | novisc.com | ||
| Capeypharmasp. z o.o. | $723,168.08 | capeypharma.com | ||
| Biotic Biomesp. z o.o. | $689,147.75 | bioticbiome.pl | ||
| Goodwill Pharma Polskasp. z o.o. | $664,724.30 | goodwillpharma.com | ||
| Pharmnewsp. z o.o. | $651,236.76 | pharmnew.pl | ||
| Pro Pedissp. z o.o. | $635,740.48 | propedis.pl | ||
| Dental Solutionssp. z o.o. | $611,683.37 | dentalsolutions.pl |
Change history
| Date | Event | |
|---|---|---|
| 2025-10-17 | Address change (Ul. Zbożowa 3/16, 30-002, Kraków → Ul. Szańcowa 44/1, 01-458, Warszawa) | |
| 2018-07-10 | Address change (Ul. Jana Pietrusińskiego 3/3, 30-321, Kraków → Ul. Zbożowa 3/16, 30-002, Kraków) | |
| 2018-03-23 | Entered in the register |
FAQ
The main business activity of Poulsard focuses on wholesale of pharmaceutical goods.
The company was registered in the Polish National Court Register (KRS) on March 23, 2018.
The headquarters is located at: ul. Szańcowa 44, 01-458 Warszawa.
The management board consists of: Andrii Andreichenko (President of the Management Board) and Valentyna Kirku (Member of the Management Board).
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.
In 2025, the company generated total revenue of USD 874,985, representing a decrease of 50.1% compared to 2024.
No, the company recorded a net loss of USD 28,875 in 2025. For comparison, in 2024 the loss was USD 1,289, representing a multi-fold increase in the loss compared to 2024.
The largest operating cost category falls under cost of goods and materials sold. This category amounted to USD 878,300 in 2025, representing 98% of all operating expenses.
Last updated: 2026-10-14